Efficacy of ciclesonide and fluticasone propionate in adult patients with moderate and severe persistent asthma (18 to 75 y) (BY9010/IT-101)

Study identifier:BY9010/IT-101

ClinicalTrials.gov identifier:NCT00163319

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Comparison of inhaled ciclesonide (640 mcg/day) and fluticasone propionate (1000 mcg/day) in patients with moderate and severe persistent asthma

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

Study drug

Ciclesonide

Sex

All

Actual Enrollment

500

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 01 Nov 2004

Primary Completion Date: -

Study Completion Date: 01 Nov 2005

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2016 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

BY9010-IT-101-RDS-2006-09-21.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Investigators

Principal Investigator

AstraZeneca AstraZeneca

AstraZeneca